SEOUL, November 04 (AJP) - Samsung Biologics said on Tuesday that it has surpassed last year’s total orders, securing 5.5 trillion won (about $4 billion) in contracts so far this year — the highest annual performance since the company was founded.
The announcement came as the South Korean biopharmaceutical manufacturer disclosed a new 275.9 billion won deal with a European drugmaker, adding to a string of large contracts signed in 2024. The company has completed eight new or expanded agreements this year, including a record 2 trillion won contract in January and another worth 1.8 trillion won with a U.S. pharmaceutical company in September.
Samsung Biologics said its cumulative order volume now exceeds $20 billion (28.7 trillion won), underscoring its growing role as one of the world’s leading contract development and manufacturing organizations (CDMOs). The company counts 17 of the world’s 20 largest pharmaceutical firms among its clients.
To meet surging global demand for biopharmaceutical production, Samsung Biologics has continued to expand its manufacturing capacity. The company’s fifth plant, which began operations in April, has increased total capacity to 784,000 liters — the largest single-site production capability in the world.
The company also cited a 99 percent batch success rate and 394 regulatory manufacturing approvals from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency as of October.
“This achievement is a result of customer trust and our focus on quality-driven management, achieved through close collaboration with our global partners,” said John Rim, the company’s chief executive, in a statement.
* This article, published by Aju Business Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.
